Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

Eur Urol. 2024 Mar;85(3):306. doi: 10.1016/j.eururo.2023.10.019. Epub 2023 Nov 11.

Authors

Carlos Toribio-Vázquez¹, Luis Martinez-Piñeiro²

Affiliations

¹ Urology Department, Hospital Universitario La Paz, Madrid, Spain; Autonomous University of Madrid, Madrid, Spain. Electronic address: carlost@uic.es.
² Urology Department, Hospital Universitario La Paz, Madrid, Spain.

PMID: 37957046
DOI: 10.1016/j.eururo.2023.10.019

No abstract available

Publication types

Randomized Controlled Trial
Multicenter Study
Clinical Trial, Phase III

MeSH terms

Antibodies, Monoclonal, Humanized*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Carcinoma, Renal Cell* / surgery
Double-Blind Method
Follow-Up Studies
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Kidney Neoplasms* / surgery
Nephrectomy / adverse effects

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized